Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2019-03-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about changes in accounting policies, including detailed explanations of the reasons for the changes, the specific accounting standards affected, and the impact on financial statements. It references regulatory accounting standards issued by the Ministry of Finance and includes approvals from the board of directors, independent directors, and the supervisory board. The document does not contain actual financial statements or comprehensive financial performance data but rather focuses on the policy change announcement and its rationale. The document length is 3632 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it is not an Annual Report (10-K) or Interim Report (IR), nor is it a certification or regulatory filing. It is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement about accounting policy changes that does not fit into other specific categories.
2019-03-28 Chinese
2018年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2018 年年度报告全文" which translates to "2018 Annual Report Full Text" for 福安药业（集团）股份有限公司 (Fuan Pharmaceutical Group Co., Ltd.). It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, risk factors, governance, and financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial data, management statements, and detailed business and financial analysis for the fiscal year 2018. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2018
2019-03-28 Chinese
关于2018年度募集资金实际存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a special report on the actual deposit and use of raised funds for the fiscal year 2018 by 福安药业（集团）股份有限公司. It contains detailed information about the amount of funds raised, their usage, management, changes in investment projects, and compliance with regulatory requirements. It references approvals from the China Securities Regulatory Commission and includes detailed tables of fund usage, project changes, and financial figures related to fundraising activities. The document is comprehensive and focused on the management and use of capital raised through stock issuance and related fundraising activities. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is not an annual report, audit report, or earnings release, but a detailed report on the use of raised funds, which fits best under CAP.
2019-03-28 Chinese
独立董事2018年度述职报告（黎明）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2018 from 福安药业（集团）股份有限公司. It details the independent director's activities, attendance at board and shareholder meetings, opinions on various board matters, committee work, investigations, and efforts to protect investor rights during the year. The content focuses on the independent director's duties and oversight rather than presenting full financial statements or audit results. The document length is 2618 characters, which is relatively short and more consistent with a report or statement by a board member rather than a full annual report or audit report. This type of document is best classified under Board/Management Information (MANG), as it relates to board member activities and governance reporting rather than financial results or audit findings.
2019-03-28 Chinese
关于举行2018年度网上业绩说明会的通知
AGM Information Classification · 95% confidence The document is a notice about holding an online performance explanation meeting for the 2018 fiscal year. It mentions the 2018 annual report has already been published and provides details about the upcoming online meeting where company executives will discuss the company's operations. The document is short (565 characters) and serves as an announcement for an event related to the annual report, not the report itself. Therefore, it fits the category of AGM Information (AGM-R), as it is about an annual general meeting or related presentation.
2019-03-28 Chinese
2018年年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (347 characters) stating that the full 2018 Annual Report and its summary will be disclosed on a specific date and website. It explicitly mentions the report will be published later and advises investors to check the disclosure site. There is no actual financial data or report content included, only a notice about the upcoming report release. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2019-03-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.